Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)
Primary Purpose
Gastrointestinal Stromal Tumor
Status
Temporarily not available
Phase
Locations
Study Type
Expanded Access
Intervention
Everolimus
Sponsored by
![The University of Texas Health Science Center at San Antonio](https://trials-media.s3.amazonaws.com/orgs/the-university-of-texas-health-science-center-at-san-antonio.jpeg)
About this trial
This is an expanded access trial for Gastrointestinal Stromal Tumor
Eligibility Criteria
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT03493152
First Posted
April 2, 2018
Last Updated
June 15, 2023
Sponsor
The University of Texas Health Science Center at San Antonio
1. Study Identification
Unique Protocol Identification Number
NCT03493152
Brief Title
Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)
Official Title
Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)
Study Type
Expanded Access
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Temporarily not available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The University of Texas Health Science Center at San Antonio
4. Oversight
5. Study Description
Brief Summary
Single patient treatment with everolimus.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastrointestinal Stromal Tumor
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Everolimus
Other Intervention Name(s)
Zortress, Afinitor, and Afinitor Disperz
Intervention Description
mTOR inhibitor
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
12. IPD Sharing Statement
Learn more about this trial
Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)
We'll reach out to this number within 24 hrs